![]() No research on the role of 8-oxo-dGTP in the prevention of tumorigenesis and against tumors has been reported either at home or abroad. ![]() 8-oxodG can be mismatched with adenine (A), and the efficiency of the mismatching is almost equivalent to that of the match with cytosine (C), resulting in the base transversion of A: T→G: C, which is the theoretical basis of DNA mutations caused by reactive oxygen species. Reactive oxygen species and oxygen-derived free radicals cause DNA oxidative damage mainly in the following two ways: one is where the guanine in the DNA strand is directly oxidized into 8-oxo-guanosine (8-oxoG) the other is where deoxyguanosine triphosphate (dGTP) in the pool of nucleotides is oxidized into 8-oxo-deoxyguanosine triphosphate (8-oxo-dGTP). In nucleic acids, more than 20 kinds of oxidized bases have been detected, among which guanine has the lowest oxidation potential and the C atom at position 8 is the most easily oxidized by hydroxyl radicals to generate 8-oxo-guanosine (8-oxoG), and therefore, 8-oxoG is the most abundant oxidized base in the cell and plays a key role in influencing the stability of genetic information. Either during normal metabolic activity or under exogenous stimuli, cells will produce a large amount of reactive oxygen species and oxygen-derived free radicals, wherein -OH is highly reactive and can damage biological macromolecules such as carbohydrates, nucleic acids, lipids and amino acids. The 8-oxo-deoxyguanosine triphosphate (8-oxo-dGTP or 8-oxodGTP) is a nucleotide that is capable of triggering DNA mutations in vivo. The present invention relates to a medicament for the prevention and treatment of tumors, in particular to the use of 8-oxo-deoxyguanosine triphosphate (8-oxo-dGTP) in the manufacturing of a medicament for the treatment, prevention and/or control of tumors, and a medicament comprising 8-oxo-dGTP for the prevention and treatment of tumors, and falls within the pharmaceutical field. China, which are incorporated herein by reference in their entireties. 29, 2016 in the State Intellectual Property Office of P.R. PCT/CN2017/084571, filed on May 16, 2017, and claims priority to and benefit of Chinese Patent Application No. ![]() national phase application of PCT Patent Application Serial No.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |